CRP is an important marker in the prediagnostics and treatment follow up of the new coronavirus (2019-nCoV).

Situation update and how CRP is used

C-reactive protein (CRP) is one of the key markers needed to diagnose and follow up the treatment of the novel coronavirus (2019-nCoV). In practice, every single patient that comes to the fever clinics/hospitals with fever and other suspected symptoms will be first checked with CRP and whole blood cell count. These routine tests help to identify a common cold from this more severe new virus infection. Further chest imaging and nucleic acid test are used to confirm the coronavirus infection. During the treatment, C-reactive protein (CRP) is also monitored together with other biochemical markers throughout the whole treatment and recovery process.

Aidian is one of the biggest suppliers of C-reactive protein (CRP) point of care products in China, the QuikRead CRP and QuikRead go CRP products manufactured in Espoo, Finland, have been registered and marketed in China since early 2000s and are regarded as the leading industry standard in terms of both performance and quality. Aidian is supporting in the fight against the spread of the novel Coronavirus (2019-nCoV) and we and our partners in China are working hard together to supply the needed extra amount of QuikRead go instruments and CRP reagents to Hubei Province and other virus affected areas.

Aidian will continue to act with the highest standards of ethics and integrity in the fight against this newly discovered virus that has affected the lives of millions of people both in China and worldwide.